She was three days out from retrieval, alone in a hotel room, hours from home.
The bloating had crept up her ribs overnight.
Then came the tightness in her chest, like something pressing where her heart beat.
That's not a rare story in donor forums.
It's also not what most donors are told to expect.
If you already did one easy cycle and got waved into a second, harder one, this is for you.
The night it started with just a little bloating
It always starts small.
A little bloating, some pressure, nothing that feels like an emergency.
One donor described it as feeling "bubbles around my collarbone."
By the next night she couldn't lie flat.
She had to sleep propped up just to breathe.
Nobody had told her fluid could build around her lungs, days after she felt fine.
By the time she understood what was happening, she was already alone with it.
That's the part clinics don't put in the intake packet.
Why a good first cycle told her nothing about the second
Monica's first cycle was easy.
No pain worth mentioning, no time off work, nothing that matched the horror stories online.
So when her second cycle came with a higher dose, she didn't ask why.
"Nobody told me that a good first cycle doesn't mean anything for the second one," she says.
She assumed her body had proven itself.
It hadn't.
It had just gotten lucky once.
Nobody explained why her dose went up
The increase came up almost as an aside.
She was told not to worry about it.
She didn't push back, because nothing in her first cycle gave her a reason to.
What she wasn't told was that a higher dose raises her risk, too.
More medication means more follicles, more estrogen, more fluid shift after retrieval.
That's the mechanism behind OHSS itself.
Raise the dose, and you raise the odds her body overreacts.
What under 2% actually means and what it leaves out
Ask a clinic about OHSS risk and you'll likely hear "under 2%."
That figure traces back to ASRM, which puts severe OHSS at roughly 1 to 2%.
It sounds definitive.
It also only counts severe cases, the ones bad enough to hospitalize someone.
It says nothing about the donor who gains eight pounds in two days and can't get off the couch.
It says nothing about Monica, doubled over in pain but not, yet, in an ER.
Mild moderate severe and the number nobody asks for
HFEA, the UK's fertility regulator, counts it differently.
About a third of patients get some form of mild OHSS, by that count.
A third.
Compare that to the "under 2%" a clinic quotes at intake, and the two numbers aren't actually arguing.
They're describing different things.
If even the professional bodies disagree, that's not proof nobody knows.
It's proof you're asking one question when you need three.
Even the peer-reviewed sources measure this differently from each other, which is exactly why one flat number never settles it.
Per cycle versus per person the gap that matters
Here's the part that matters for someone weighing a third cycle.
Most clinic statistics are per cycle, not per donor.
Do two cycles, and you've taken that per-cycle risk twice.
Do three, and you've taken it three times, with a higher dose stacked on top.
Nobody frames it that way at intake.
They hand you one number and let you assume it resets every time.
It doesn't.
The call that ended with drink water and take a painkiller
When symptoms get bad, donors call the clinic.
A common answer: drink more water, take a painkiller, wait it out.
For mild bloating, that might be fine.
For someone with fluid creeping toward her lungs, it isn't.
The problem is nobody on that call always knows which one you are.
Symptoms that seem manageable on the phone can escalate within a day, sometimes within hours.
That gap, between wait-and-see and get-to-an-ER, is where the real danger sits.
If you were told OHSS was rare during counseling, it's easy to assume your symptoms are just a hard recovery instead of the thing you were warned about.
When bloating stops being normal recovery
Where's the line.
Rapid weight gain, several pounds in a day or two, is one flag.
Shortness of breath, or needing to sleep sitting up, is another.
Severe abdominal pain that keeps building, instead of easing, is a third.
Vomiting that doesn't stop after a day is a fourth.
You might not know yet who pays for an ER visit.
That question shouldn't be the reason you don't go.
Any one of those symptoms is worth the visit, whatever the nurse on the phone says.
Why the second cycle is often the harder one
This is the piece Monica needed before she said yes to cycle two.
A higher dose doesn't just mean more eggs.
It means more follicles producing more estrogen, which drives the fluid shift behind OHSS.
Donors who had an easy first round sometimes get a second round with more stimulation.
The assumption is that their body already proved it could handle more.
That assumption is the mechanism failing in plain sight.
A body that tolerated one dose doesn't automatically tolerate a bigger one.
What actually changes the risk not just the dose
Dose isn't the only lever.
Trigger choice matters too.
A GnRH-agonist trigger, instead of the standard hCG trigger, is associated with lower OHSS risk in the research.
If a clinic raises your dose without mentioning trigger type, that's worth asking about directly.
The point isn't refusing a second or third cycle outright.
It's asking what specifically changed, and why, before you agree to it.
Deciding whether a third cycle is worth it
Compensation is real, and so is the pull of it.
But "worth it" depends on information Monica didn't have going into cycle two.
What was her actual egg count last time.
Which symptoms crossed from uncomfortable into dangerous.
Whether the clinic is proposing the same dose, a higher one, or a different trigger this time.
Answering those isn't paranoia.
It's the minimum before signing up for round three.
A clinic pushing for a higher yield without answering those questions is worth sitting with, even if you can't prove the motive.
Getting the answers before you sign anything
None of this means every repeat cycle ends badly.
Plenty of donors go through several cycles with no crisis at all.
But going in blind, the way Monica did between cycle one and two, is the actual risk factor.
Whether the industry ever puts a fuller number in its intake packet is a separate fight.
That one belongs to advocates, and it's worth having.
Right now, the fight in front of you is smaller.
Get your own numbers, your own dose, your own trigger, before you decide anything else.